AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piper, K. E.
Right arrow Articles by Patel, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piper, K. E.
Right arrow Articles by Patel, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2554-2556, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Trovafloxacin Treatment of Viridans Group Streptococcus Experimental Endocarditis

Kerryl E. Piper,1 Mark S. Rouse,1 Karen L. Ronningen,1 James M. Steckelberg,1 Walter R. Wilson,1 and Robin Patel1,2,*

Division of Infectious Diseases, Department of Internal Medicine,1 and Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology,2 Mayo Clinic and Foundation, Rochester, Minnesota

Received 11 November 1999/Returned for modification 30 March 2000/Accepted 12 June 2000

The activity of trovafloxacin was compared with those of vancomycin and penicillin in a model of Streptococcus sanguis species group (trovafloxacin MIC, 0.125 µg/ml) and Streptococcus mitis species group (trovafloxacin MIC, 0.125 µg/ml) experimental endocarditis. Rabbits with catheter-induced aortic valve vegetations were given no treatment, trovafloxacin at 15 mg/kg of body weight three times a day (t.i.d.), vancomycin at 15 mg/kg twice a day, or penicillin at 1.2 × 106 IU t.i.d. After 3 days of treatment, the animals were sacrificed; cardiac valve vegetations were aseptically removed and cultured quantitatively. Penicillin was as active as vancomycin as measured by in vivo clearance of bacteria. Trovafloxacin was less active (P < 0.05) than vancomycin or penicillin against S. sanguis species group infection but had similar efficacy against S. mitis species group infection. Quinolones, despite MICs in the susceptible range, may not be active for serious infections caused by some viridans group streptococci.

* Corresponding author. Mailing address: Division of Infectious Diseases, Division of Clinical Microbiology, Mayo Clinic and Foundation, Rochester, MN 55905. Phone: (507) 284-3021. Fax: (507) 284-9859. E-mail: patel.robin{at}mayo.edu.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2554-2556, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.